Per Lundin
Direktor/Vorstandsmitglied bei COMBIGENE AB
Profil
Dr. Per Lundin is a Chief Executive Officer & Director at Evox Therapeutics Ltd.
He is on the Board of Directors at Evox Therapeutics Ltd., JDRF International and CombiGene AB.
Dr. Lundin was previously employed as a Non-Executive Director by IsletOne Therapeutics and a Manager-European Law Firm Market by Thomson Reuters Holdings AB.
He received his graduate degree from Royal Institute of Technology, an MBA from Stockholm Business School and a doctorate degree from Karolinska Institutet.
Aktive Positionen von Per Lundin
Unternehmen | Position | Beginn |
---|---|---|
COMBIGENE AB | Direktor/Vorstandsmitglied | 01.01.2020 |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Gründer | 01.01.2016 |
JDRF International
JDRF International Miscellaneous Commercial ServicesCommercial Services JDRF International is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. JDRF find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. It was founded in 1970 and is headquartered in New York, NY. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Per Lundin
Unternehmen | Position | Ende |
---|---|---|
IsletOne Therapeutics | Gründer | 01.04.2016 |
Thomson Reuters Holdings AB | Corporate Officer/Principal | 01.04.2016 |
Ausbildung von Per Lundin
Karolinska Institutet | Doctorate Degree |
Stockholm Business School | Masters Business Admin |
Royal Institute of Technology | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
COMBIGENE AB | Health Technology |
Private Unternehmen | 4 |
---|---|
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Health Technology |
IsletOne Therapeutics | |
Thomson Reuters Holdings AB | |
JDRF International
JDRF International Miscellaneous Commercial ServicesCommercial Services JDRF International is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder of and advocate for type 1 diabetes research. JDRF find a cure for diabetes and its complications through the support of research. Type 1 diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal. Until a cure is found, people with type 1 diabetes have to test their blood sugar and give themselves insulin injections multiple times or use a pump each day, every day of their lives. And even with that intensive care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may include kidney failure, blindness, heart disease, stroke, and amputation. It was founded in 1970 and is headquartered in New York, NY. | Commercial Services |